Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. covers events occurring on March 8, 2018, and March 10, 2018, with the report filed on March 14, 2018. The filing addresses corporate governance changes, specifically the resignation of a director and an amendment to the company's bylaws.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and legal amendments rather than financial performance.
Material Changes
- Director Resignation: Kevin P. Starr resigned from the Board of Directors, effective March 31, 2018. The resignation was not caused by any disagreement with the Company regarding operations, policies, or practices.
- Audit Committee Restructuring: Upon Mr. Starr's resignation, Marsha H. Fanucci will become Chair of the Audit Committee, with Michael W. Bonney and John K. Clarke serving as members.
- Bylaws Amendment: On March 8, 2018, the Board approved Amendment No. 2 to the Amended and Restated Bylaws. This amendment clarifies and modernizes methods for holding stockholder meetings to include meetings conducted solely by remote communication, as authorized by Delaware law.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, risks, contingencies, or unusual items. The document is limited to reporting the specific governance events listed above.
Investor Verification Checklist
- Verify the effective date of Kevin P. Starr's resignation (March 31, 2018).
- Confirm the new composition of the Audit Committee (Chair: Marsha H. Fanucci; Members: Michael W. Bonney, John K. Clarke).
- Review Exhibit 3.1 for the full text of Amendment No. 2 to the Bylaws regarding remote stockholder meetings.
- Note that no financial data is included in this specific filing; refer to the most recent 10-K or 10-Q for financial metrics.